Paradigm Therapeutics Ltd Company Profile

22:45 EDT 20th September 2018 | BioPortfolio

Paradigm Therapeutics was founded in 1999 and has established world class target identification and validation capabilities based on gene knock out technology and in vivo pharmacology. The acquisition of Amedis Pharmaceuticals in January 2005 added key medicinal chemistry skills. The combined company has focused on the identification of novel, small molecule tractable targets with defined therapeutic utility within key gene families such as G-protein coupled receptors (GPCRs), ion channels and proteases. The company has developed a drug discovery pipeline comprising targets and late stage pre-clinical projects in key areas of unmet medical need in pain, CNS disorders, hormone dependent diseases such as prostate and breast cancer and metabolic diseases such as diabetes, hyperlipidemias, obesity and osteoporosis. In June 2005 Paradigm Therapeutics announced two major collaborations with Ortho-McNeil Pharmaceuticals (J&J) in pain and urinary urge incontinence and with Takeda in CNS disorders. The company is based in Cambridge UK and Singapore.


418 Cambridge Science Park
United Kingdom


Phone: 44 (0)1223 477910
Fax: 44 (0)1223 477911

News Articles [845 Associated News Articles listed on BioPortfolio]

CLL Paradigm Continues to Be Refined

Erlene Seymour, MD, discusses novel therapies as well as their potential applications in the treatment paradigm of chronic lymphocytic leukemia.

Paradigm Spine announces leadership changes

Paradigm Spine tapped Francis Magee, who has 25 years of orthopedic and spine device industry experience, to serve as its chi -More- 

Paradigm Spine scores reimbursement win for stabilization implant

Paradigm Spine has obtained coverage from Blue Cross Blue Shield of South Carolina for its coflex interlaminar stabilization  -More- 

FDA OKs Paradigm Spine's interlaminar stabilization system

Paradigm Spine's Coflex interlaminar stabilization disposable instrument kit has been granted premarket approval by the FDA.  -More- 

CDRH’s New Post-Market Paradigm: Why The Public Should Be Worried

Strengthening the flow of real-world evidence on medical devices is at the heart of US FDA's evolving paradigm of device...   

Paradigm Spine gets FDA pre-market approval for disposable instrument kit

Paradigm Spine has secured pre-market supplemental approval (PMA) from the US Food and Drug Administration (FDA) for its coflex Interlaminar Stabilization disposable instrument kit.

The microbiome – a novel paradigm in oncology research

Alasdair Scott of Imperial College, London, discusses our Special Issue "The microbiome - a novel paradigm in oncology research". This special issue explores the rapidly evolving field of the microbi...

Bristol-Myers Squibb (BMY) Shares Sold by Paradigm Asset Management Co. LLC

Paradigm Asset Management Co. LLC lessened its position in shares of Bristol-Myers Squibb by 6.1% in the first quarter, according to the company in its most recent disclosure with the Securities &...

PubMed Articles [659 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Pilot for novel context generalization paradigm.

Following an aversive experience, fears often generalize across contexts. Contextual fear generalization is modeled in a laboratory paradigm in which one context (CTX+) is paired with an aversive unco...

From Child Protection to Paradigm Protection-The Genesis, Development, and Defense of a Scientific Paradigm.

A scientific paradigm typically embraces research norms and values, such as truth-seeking, critical thinking, disinterestedness, and good scientific practice. These values should prevent a paradigm fr...

Regenerative Rehabilitation: Applied Biophysics Meets Stem Cell Therapeutics.

The emerging field of regenerative rehabilitation integrates biological and bioengineering advances in regenerative medicine with rehabilitative sciences. Here we highlight recent stem cell-based exam...

Clinical Trials [387 Associated Clinical Trials listed on BioPortfolio]

Feasibility Study of Effective Methods for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness

Feasibility study to compare the effectiveness of the Paradigm Sensor Augmented System versus subjects continuing to administer insulin in multiple dose injections. Evaluate the educationa...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes

The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control whe...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Feasibility Trial of rTMS for Cannabis Use Disorder

This small pilot trial will recruit 10 cannabis use disordered participants and apply 20 sessions of rTMS in conjunction with a two session Brief Marijuana Dependance Counseling treatment ...

Companies [1321 Associated Companies listed on BioPortfolio]

Paradigm Therapeutics Incorporated

Paradigm Therapeutics is an emerging drug discovery company focussed on the pharmaceutical exploitation of the human genome. The race to define biological function of the thousands of uncharacterised ...

The Paradigm Award Committee

The Paradigm Award was created to honor hospitals that have gone above and beyond in their efforts to foster efficient labor practices without resorting to workforce reductions or dramatic top-down ma...

Paradigm Medical Industries

Founded in 1996, Paradigm Medical Industries, Inc. develops, manufactures, and markets diagnostic and surgical equipment for the ophthalmic market. The company specialized in powerful, easy-to-use, v...

Semma Therapeutics, Inc.

Semma Therapeutics is pioneering the new treatment paradigm of using cells as medicine. Semma’s new class of regenerative medicine therapies couples its breakthrough stem cel...

Nimbus Therapeutics, LLC

Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pi...

More Information about "Paradigm Therapeutics Ltd" on BioPortfolio

We have published hundreds of Paradigm Therapeutics Ltd news stories on BioPortfolio along with dozens of Paradigm Therapeutics Ltd Clinical Trials and PubMed Articles about Paradigm Therapeutics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Paradigm Therapeutics Ltd Companies in our database. You can also find out about relevant Paradigm Therapeutics Ltd Drugs and Medications on this site too.

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Corporate Database Quicklinks

Searches Linking to this Company Record